未登录 分享 收藏
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial (vol 137, pg 250, 2020) Stahler, Arndt; Stintzing, Sebastian; von Einem, Jobst C.; Westphalen (Benedikt), Christoph B.; Heinrich, Kathrin; Kraemer, Nicole; Michl, Marlies; Modest, Dominik P.; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Moehler, Markus; Kaiser, Florian; Kirchner, Thomas; Jung, Andreas; Heinemann, Volker 分享 收藏
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 Fischer, Laura E.; Stintzing, Sebastian; von Weikersthal, Ludwig Fischer; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmueller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Heinemann, Volker 分享 收藏
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306) 早期体重减轻是在随机III期试验FIRE-3 (AIO KRK-0306) 中接受一线治疗的转移性结直肠癌患者生存期缩短和副作用增加的独立危险因素 Liu, Lian; Erickson, Nicole Tonya; Ricard, Ingrid; von Weikersthal, Ludwig Fischer; Lerch, Markus M.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Hoeffkes, Heinz-Gert; Moehler, Markus; Gesenhues, Alena Britta; Theurich, Sebastian; Michl, Marlies; Modest, Dominik P.; Alguel, Hana; Stintzing, Sebastian; Heinemann, Volker; Holch, Julian W. 分享 收藏
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial FOLFIRI联合西妥昔单抗或贝伐珠单抗治疗晚期结直肠癌：FIRE‑3随机对照试验的最终生存期及按方案分析结果 Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmuller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian 分享 收藏
Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study von Einem, J. C.; Heinemann, V.; Modest, D. P.; Stahler, A.; Miller-Phillips, L.; von Weikersthal, L. Fischer; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Jung, A.; Kirchner, T.; Stintzing, S. 分享 收藏
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial Stahler, Arndt; Stintzing, Sebastian; von Einem, Jobst C.; Westphalen (Benedikt), Christoph B.; Heinrich, Kathrin; Kraemer, Nicole; Michl, Marlies; Modest, Dominik P.; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Moehler, Markus; Kaiser, Florian; Kirchner, Thomas; Jung, Andreas; Heinemann, Volker 分享 收藏
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC 通过CD31评估的微血管密度预测贝伐单抗治疗转移性结直肠癌的临床益处: pivotor研究的结果，卡培他滨和伊立替康加贝伐单抗，然后卡培他滨和奥沙利铂加贝伐单抗或反向序列的转化前瞻性II期研究 Bianconi, Daniela; Herac, Merima; Posch, Florian; Schmeidl, Margit; Unseld, Matthias; Kieler, Markus; Brettner, Robert; Muellauer, Leonhard; Riedl, Jakob; Gerger, Armin; Scheithauer, Werner; Prager, Gerald 分享 收藏
分享 收藏
分享 收藏
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group 贝伐单抗作为结肠癌的辅助治疗: 来自GERCOR组的s-avant III期研究的更新结果 Andre, T.; Vernerey, D.; Im, S. A.; Bodoky, G.; Buzzoni, R.; Reingold, S.; Rivera, F.; McKendrick, J.; Scheithauer, W.; Ravit, G.; Fountzilas, G.; Yong, W. P.; Isaacs, R.; Osterlund, P.; Liang, J. T.; Creemers, G. J.; Rakez, M.; Van Cutsem, E.; Cunningham, D.; Tabernero, J.; de Gramont, A. 分享 收藏
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) Holch, J. W.; Held, S.; Stintzing, S.; von Weikersthal, L. Fischer; Decker, T.; Kiani, A.; Kaiser, F.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; von Einem, J. C.; Michl, M.; Heinemann, V 分享 收藏
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial Stintzing, S.; Wirapati, P.; Lenz, H. J.; Neureiter, D.; von Weikersthal, L. Fischer; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Moehler, M.; Scheithauer, W.; Held, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Aderka, D.; Tejpar, S.; Heinemann, V 分享 收藏
分享 收藏
分享 收藏
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores Gargiulo, Piera; Dietrich, Daniel; Herrmann, Richard; Bodoky, Gyorgy; Ruhstaller, Thomas; Scheithauer, Werner; Glimelius, Bengt; Berardi, Simona; Pignata, Sandro; Brauchli, Peter 分享 收藏
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial) 基线癌胚抗原与FOLFIRI联合西妥昔单抗或贝伐单抗一线治疗转移性结直肠癌的相关性 (FIRE-3试验) Holch, J. W.; Ricard, I.; Stintzing, S.; von Weikersthal, L. Fischer; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; von Einem, J. C.; Michl, M.; Heinemann, V. 分享 收藏
分享 收藏
Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma Cunningham, D.; Van Cutsem, E.; Salazar, R.; Ducreux, M.; Scheithauer, W.; Sclafani, F.; Wiegert, E.; Schmidt, M.; Tournigand, C.; Sobrero, A.; Arnold, D. 分享 收藏
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial Holch, Julian Walter; Ricard, Ingrid; Stintzing, Sebastian; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmueller, Christian; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Scholz, Michael; Mueller, Sebastian; Link, Hartmut; Rost, Andreas; Hoeffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard Udo; Miller-Phillips, Lisa; Kirchner, Thomas; Jung, Andreas; von Einem, Jobst Christian; Modest, Dominik Paul; Heinemann, Volker 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
OAAI